CD274 and glioblastoma: Furthermore, MC9999 CAR T cells exhibited activity against a diverse set of PD-L1-expressing, solid tumor-derived target cells that included an NSCLC cell line (Calu-1), a melanoma cell line (SH-4), a GBM cell line (LN229), and, finally, two patient-derived GBM cell lines.